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Chikungunya virus (CHIKV; genus Alphavirus) is the causative agent of chikungunya fever. CHIKV replication can be in-
hibited by some broad-spectrum antiviral compounds; in contrast, there is very little information about compounds spe-
cifically inhibiting the enzymatic activities of CHIKV replication proteins. These proteins are translated in the form of a
nonstructural (ns) P1234 polyprotein precursor from the CHIKV positive-strand RNA genome. Active forms of replicase
enzymes are generated using the autoproteolytic activity of nsP2. The available three-dimensional (3D) structure of nsP2
protease has made it a target for in silico drug design; however, there is thus far little evidence that the designed com-
pounds indeed inhibit the protease activity of nsP2 and/or suppress CHIKV replication. In this study, a set of 12 com-
pounds, predicted to interact with the active center of nsP2 protease, was designed using target-based modeling. The ma-
jority of these compounds were shown to inhibit the ability of nsP2 to process recombinant protein and synthetic peptide
substrates. Furthermore, all compounds found to be active in these cell-free assays also suppressed CHIKV replication in
cell culture, the 50% effective concentration (EC50) of the most potent inhibitor being1.5 M. Analysis of stereoisomers
of one compound revealed that inhibition of both the nsP2 protease activity and CHIKV replication depended on the con-
formation of the inhibitor. Combining the data obtained from different assays also indicates that some of the analyzed
compounds may suppress CHIKV replication using more than one mechanism.
Chikungunya virus (CHIKV; genus Alphavirus, family Toga-viridae) is the causative agent of chikungunya fever, a disease
that has affected millions in the last decade. It is characterized by
high fever, arthralgia, myalgia, headache, and rash. The disease is
usually self-limiting; however long-lasting chronic symptoms are
observed in nearly 50% of CHIKV-infected patients (1). As there
is no approved vaccine or specific licensed antiviral compounds
(2), the treatment of CHIKV infection is largely based on relief of
symptoms.
CHIKV infection can be inhibited by targeting host factors
essential for virus infection. Targeting of several metabolic path-
ways has revealed anti-CHIKV effects of several licensed drugs (3).
Compounds most likely targeting virus entry or host cell-specific
components required for virus infection have been described (4–
8). Several nucleosides or nucleotides, acting as pseudosub-
strates for CHIKV RNA-dependent RNA polymerase and/or
using another, more general mechanism of action, have shown
anti-CHIKV activity (9). In addition, anti-CHIKV effects have
been described for several groups of novel synthetic com-
pounds (10–12).
Computer-aided design based on molecular docking and mo-
lecular dynamics simulations and pharmacophore approach al-
lows identifying potential in silico hits as active inhibitors for dif-
ferent CHIKV replicase proteins. This approach, however,
requires the three-dimensional (3D) structures of targeted pro-
teins, advanced knowledge of the functions of the viral replicase,
and availability of robust assays. CHIKV replicase proteins, called
nonstructural (ns) proteins 1 to 4 (nsP1 to -4), are translated as
P1234 polyprotein precursors directly from the 11.8-kb genomic
RNA of the virus (13). nsP1 is a cap methyl- and guanylyltrans-
ferase and serves as the membrane anchor of replicase complexes
(14, 15). nsP2 has protease, NTPase, RNA triphosphatase, and
RNA helicase activities (16–18). The N-terminal domain of nsP3
has ADP-ribose protein hydrolase and relatively poor ADP-ribose
1-phosphohydrolase activities (19, 20), while nsP4 is the RNA-
dependent RNA polymerase and, most likely, also a terminal ad-
enylyltransferase (13). The activities of CHIKV nsP2 are relatively
easy to analyze using purified recombinant proteins, and very re-
cently, an assay for inhibitors of CHIKV nsP1 was developed (21).
A combination of cell-based and cell-free assays was successfully
used to identify inhibitors targeting nsP1 of CHIKV (22). In ad-
dition, the activities of ns proteins can indirectly be analyzed using
recently developed CHIKV trans-replication system or an assay
based on the use of extracts derived from infected cells (23, 24).
Thus far, only the structures of the C-terminal region of nsP2
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(PDB code 3TRK) and the N-terminal macro domain of nsP3
(25), together comprising only20% of the ns region of CHIKV,
have been resolved. A combination of virtual screening and mo-
lecular dynamic simulations has allowed finding three different
target sites in the macro domain of CHIKV nsP3. Altogether,
1,541 compoundswere subsequently screened by docking them to
these nsP3 sites. The best binding free energies (G) of lead com-
pounds that presumably target CHIKV nsP3 ranged between
8.3 and 11.1 kcal/mol (26).Notably, the structures of these com-
pounds were very different, and their ability to inhibit nsP3 or the
actual virus has not been demonstrated.
Alphavirus nsP2 protease consists of two different domains
(27). This region is folded similarly in nsP2s of different alphavi-
ruses and thus represents a potential target both for specific and
pan-alphavirus protease inhibitors. Virtual screening in the ZINC
database using the Glide module by Schrödinger LLC has been
carried out (28–30). Molecular docking was carried out using the
hypothetical CHIKV nsP2 protease active site in the area of the
catalytic amino acid residues Cys1013, His1083, and Trp1084
(here and below, the amino acid residues are numbered from the
N terminus of P1234). For the top 10 hits, the best binding free
energies were found to be in the range of 9.145 to 9.609 kcal/
mol. The compounds with the highest predicted activity,
5-fluoro-N-[2-(2-imidazol-1-yletoxy)phenyl]-1H-indol-2-car-
boxamide and N-[2-(imidazole-1-ylmethyl)phenyl]-2-methyl-
benzamide, have rather different molecular structures, although
in both cases the benzamide bridge is involved as a linker. Simi-
larly, several potential inhibitors were identified using a combina-
tion of molecular docking, virtual screening, and molecular dy-
namics simulations on the crystal structure of CHIKV nsP2
protease (31). The best compounds were characterized by binding
free energies up to10.6 kcal/mol. However, in these studies the
ability of the predicted compounds to inhibit the protease activity
of CHIKV nsP2 was not demonstrated.
Venezuelan equine encephalitis virus (VEEV) nsP2 protease
structure (PDB code 2HWK [27]) was initially used for modeling
the 3D structure of CHIKV protease (32), and using molecular
docking, several potential virus inhibitors were predicted. Al-
though no quantitative correlation was established between dock-
ing efficiency and experimentallymeasured virus inhibition, some
inhibitors were shown to be active in cell-based assays with 50%
effective concentrations (EC50s) between 3.2 and 6.4 M. Simi-
larly, different arylalkylidene derivatives of 1,3-thiazolidin-4-one,
predicted to interact with the protease part of nsP2, were found to
inhibit CHIKV replication inVero cells at concentrations between
0.42 and 40.1 M (30). However, again, neither of these studies
provided experimental proof that the protease activity of nsP2was
indeed targeted by the analyzed compounds. Other inhibitors tar-
geting nsP2 include peptidomimetic compounds designed using
quantummechanics-based ligand descriptors. These compounds
were verified using cell culture assays, in which the most active of
them had EC90s of 8.76 to 9.57 g/ml (33). For the protease of
VEEV, a crystal structure of the enzymewith such an inhibitor has
been recently resolved, clearly confirming the targeting of nsP2
and demonstrating themode of binding of peptidomimetic inhib-
itors (34).
As highlighted above, thus far the common drawback of
CHIKV inhibitors originating from computer-aided design is the
lack of experimental verification of their antiviral activity and/or
target specificity. The protease activity of nsP2 is robust and can be
easily analyzed (35, 36). Such analysis represents the only option
to provide direct proof regarding the true molecular target of the
designed compounds, information regarding the exact mecha-
nism of inhibition, and valuable input data for subsequent opti-
mization of inhibitor structure. In this study, for the first time, we
combined the power of computer-aided inhibitor design with
careful verification of the effects of selected compounds both on
the protease activity of CHIKV nsP2 and on the replication of
CHIKV in cell culture. From our rationally designed and tested
compounds, the most promising compound shows an EC50 of
1.5 M, with a G of8.61 kcal/mol. Overall, the results rep-
resent, to our knowledge, the first set of compounds proven to
inhibit the protease activity of CHIKV nsP2 and also demon-
strated to directly inhibit CHIKV replication.
MATERIALS AND METHODS
Molecular design. The crystal structure of CHIKV nsP2 protease was
obtained from the Protein Data Bank (PDB code 3RTK). The hydropho-
bic hydrogen atomswere added to the structure for furthermodeling (37),
and docking was performed essentially as previously described (30). In
docking simulations, the nsP2 protein was kept as a rigid molecule. The
ligandswere optimized beforemolecular docking using the semiempirical
quantum-chemical RM1methodwithin the programMaestro 9.5 (37). In
all simulations the active site was first surrounded with a grid box at 70 by
70 by 70 Å. The AutoDock 4.2 specific force-field (37) was used for calcu-
lating interactions between CHIKV nsP2 protease and the predicted in-
hibitor molecules. All compounds, except those synthesized in-house,
were obtained from MolPort.
Synthesis of compounds 1a to 1d and 1aL to 1dL. Diastereomeric
compounds 1a to 1d were synthesized starting from commercially avail-
able 3,4-dimethylbenzaldehyde as shown below in Fig. 6. The latter was
first converted into 3,4-dimethylstyrene by Wittig olefination, and the
obtained olefin was cyclopropanated with ethyl diazoacetate to afford a
mixture of cis- and trans-ethyl esters of 2-arylcyclopropanecarboxylic acid
(cis/trans ratio 35:65). After selective alkaline hydrolysis, the pure trans-
isomer of 2-arylcyclopropanecarboxylic acid was isolated. Unreacted cis-
ethyl ester was further converted into the corresponding cis-2-arylcyclo-
propanecarboxylic acid by treatment with excess alkali solution at an
elevated temperature (see the supplemental material for detailed experi-
mental procedures). The obtained cis- and trans-acids were transformed
into the corresponding acid chlorides prior to the acylation of D-()-
phenylglycinamide to afford target compounds 1a-1b and 1c-1d as
equimolecular mixtures of diastereomers in 63% and 79% combined
yields, respectively. Small amounts (50 mg) of the obtained mixtures
were separated by column chromatography on a silica gel using a gradient
of toluene in ethyl acetate as an eluent. The configuration of the stereo-
centers in the cyclopropane ring was assigned with the aid of nuclear
magnetic resonance (NMR) spectroscopy and assisted conformational
analysis. Enantiomeric counterparts 1aL to 1dLwere prepared in the same
manner using L-()-phenylglycinamide instead of its D-()-enantiomer
in the last step. Details of the synthesis, purification, and NMR spectra of
the compounds and determination of the relative conformations of com-
pounds 1a to 1d are provided in the supplemental material.
Cell lines and viruses. BHK-21 cells (ATCC CCL-10) were grown at
37°C in a 5% CO2 atmosphere in Glasgow’s minimal essential medium
(GMEM; Gibco) containing 10% fetal bovine serum, 2% tryptose phos-
phate broth, 200 mM HEPES, 100 U/ml of penicillin, and 0.1 mg/ml of
streptomycin.
In virus-based experiments, wild-type (wt) CHIKV isolate LR-2006-
OPY1 (East/Central/South African genotype) derived from an infectious
cDNA clone (5) was used. For EC50 determination, a derivative of this
clone harboring a sequence encoding aRenilla luciferase (Rluc)marker in
the nsP3 coding region, referred to as CHIKV-Rluc (5), was used.
Chikungunya Virus nsP2 Inhibitors
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Production of protease and substrates. Full-length recombinant
CHIKV nsP2 was used as the protease in all cell-free assays. Recombinant
protein substrate contained the nsP2 cleavage site (P10 to P=5) from the
nsP1/nsP2 junction, placed between enhanced green fluorescent protein
(EGFP) and thioredoxin. The recombinant proteins were expressed and
purified as described in detail earlier (16, 36). Briefly, CHIKV nsP2 was
expressed in Escherichia coli and the thioredoxin tag was removed by au-
tocatalytic cleavage. Recombinant nsP2 was purified using metal affinity,
cation-exchange, and size exclusion chromatography. The recombinant
protease substrate was expressed and purified using the same procedures
except that the clarified bacterial lysate was first passed through preswol-
len DE52 anion-exchange resin. Protein concentrations were measured
using aNanoDrop spectrophotometer (Thermo Scientific, USA), and pu-
rified proteins were flash frozen and stored at80°C.
Cell-free protease inhibition assays. Compounds obtained from
commercial sources were given specific serial numbers 1 to 12, while iso-
mers of compound 1 synthesized in-house were named 1a to 1d and 1aL
to 1dL. Stocks were prepared by dissolving compounds in sterile dimethyl
sulfoxide (DMSO; Sigma,USA) at 10mM, aliquoted, and stored at20°C
until further use.
Themaximal toleratedDMSO concentrationwas determined by vary-
ing theDMSO concentration from 2 to 30% in protease assay buffer A (20
mM HEPES [pH 7.2], 2 mM dithiothreitol [DTT]). CHIKV nsP2 (final
concentration, 348 nM) was added, themixture was incubated for 10min
at 22°C, after which recombinant protein substrate was added to a final
concentration of 5.9M. The reaction was carried out at 30°C for 1 h in a
10-l volume. A protease inhibition assay using a recombinant protease
substrate was carried out as described above except that the compounds
were added to the reactionmixture at a final concentration of 1mM; 10%
DMSO was used as a solvent control. Products of protease reaction were
resolved by 10% SDS-PAGE and detected using Coomassie blue staining
as described earlier (35, 36).
A protease inhibition assay with a peptide substrate was carried out
using purified CHIKV nsP2 and a substrate representing the nsP3/nsP4
cleavage site of CHIKV P1234 polyprotein. The peptide had the sequence
DELRLDRAGG2YIFSS (arrow indicates the scissile bond), a quencher
(4-{[4-(dimethylamino)phenyl]-azo} benzoic acid; DABCYL) at the N
terminus, and a fluorescent molecule {5-[(2=-aminoethyl)-amino] naph-
thalenesulfonic acid; EDANS} at the C terminus (35). Compounds were
diluted in buffer A to a final concentration of 200 M (10 to 200 M in
some experiments); DMSOwas used as a solvent control. nsP2 was added
to a final concentration of 78 nM, and the mixture was incubated at 22°C
for 10 min, after which the protease substrate was added to a final con-
centration of 15 M. Continuous fluorescence resonance energy transfer
(FRET) measurement was carried out with an excitation wavelength of
340 nm and emission wavelength of 490 nm at 30°C using a Synergy M
microplate reader (BioTek, USA). The data were normalized and pro-
cessed usingMS Excel and expressed as relative fluorescence units (RFU).
Antiviral activity and toxicity measurements in cell culture. Antivi-
ral activity and toxicity measurements in cell culture were performed as
previously described (7). Briefly, BHK-21 cells seeded on 96-well white-
bottom culture plates (PerkinElmer) were infected with CHIKV-Rluc at a
multiplicity of infection (MOI) of 0.01 PFU/cell in infection medium
containing minimal essential medium, 0.2% bovine serum albumin, 20
mM HEPES buffer, and 1 mM L-glutamine. Protease inhibitors at final
concentrations ranging from 0.02Mto 200M(100Mfor compound
1 and its isomers) or 0.1%DMSO (solvent control) were added alongwith
the virus inoculum and were present throughout the course of the infec-
tion. The assay was carried out in triplicate wells. At 16 h postinfection the
medium was discarded, cells were lysed, and Rluc activity was measured
using a Renilla luciferase assay system (Promega) according to the man-
ufacturer’s instructions. Percent inhibition was calculated by comparing
values obtained from compound-treated wells with those from infected
wells treated with 0.1% DMSO. In parallel, BHK-21 cells were mock in-
fected and treatedwith inhibitors at final concentrations up to 200M.At
16 h posttreatment, cells were lysed and cell viability was measured using
a Cell Titer Glo cytotoxicity assay (Promega) according to the manufac-
turer’s instructions. Percent inhibition was calculated based on the read-
out frommock-infected cells containing 0.1%DMSO. EC50 and 50% cell
cytotoxicity (CC50) were calculated by generating dose-response curves
using OriginPro software.
Northern blot analysis. Ninety percent confluent BHK-21 cell cul-
tures (3	 106 cell/plate) were infected with wt CHIKV at anMOI of 10
in the presence of compounds 1c, 3, and 11 (each at 12.5 M, 25 M, 50
M, or 100 M) or 8 (0.75 M, 1.5 M, 3 M, 6 M, 12.5 M, 25 M,
50 M, or 100 M) in GMEM containing 2% bovine serum albumin
(BSA). Control cells were infected in 1%DMSO used as a solvent control.
After 1 h of incubation at 37°C, the inoculum was removed and replaced
with growth medium containing the same concentration of compounds
or DMSO. Cells were incubated at 37°C for 6 h, collected, and lysed, and
total RNA was purified using TRIzol reagent (Thermo Scientific). North-
ern blotting was carried out as previously described (36). Briefly, equal
amounts of total RNA samples (5 g) were denatured, separated by elec-
trophoresis in a 1% agarose and 6.6% formaldehyde-containing denatur-
ing gel, and transferred to a Hybond-N membrane (GE Healthcare).
Membranes were probed with a digoxigenin (DIG)-labeled RNA detec-
tion probe complementary to the 3= untranslated region of the CHIKV
genome, washed, and incubated with detection antibody (anti-digoxige-
nin-alkaline phosphatase [AP] Fab fragments; Roche); CDP-Star (ready
to use; Roche) was used to detect the hybridized signals. Finally, themem-
brane was exposed to X-ray film (medical X-ray films, blue; AGFA).
Time-of-addition assays with compounds 1c, 3, 8, and 11. For the
time-of-addition assay, BHK-21 cell cultures (3 	 106 cell/plate) were
infected with CHIKV at an MOI of 10; DMSO was used as a solvent
control. To analyze the effects of compounds on viral RNA synthesis, cells
were pretreated for 2 h with 100 M concentrations of compounds that
were discarded prior to infection with CHIKV. Alternatively, the com-
pounds were added together with virus or at 2 h postinfection and were
present until cells were harvested at 6 h postinfection. Total RNA was
purified and analyzed as described above. For the analysis of infectious
virus release, cells were treated as described above except that in one setup
the compounds were added at 4 h postinfection and the virus-containing
media were collected at 8 h postinfection. The amounts of released virions
were determined using plaque titration in BHK-21 cells.
RESULTS
Molecular design. Currently there are almost no data on the spe-
cific inhibition of the protease activity of CHIKV nsP2, either at
the level of individual enzyme or in the context of CHIKV infec-
tion. We started from the hypothesis that compounds recently
predicted by Bassetto and coauthors using molecular docking
modeling and then tested in cell culture experiments (32) indeed
act as nsP2 protease inhibitors. In order to find new CHIKV nsP2
inhibitors, compound B1 (here prefix B is used to designate com-
pounds originating from the study by Bassetto et al. [32]) was
selected as the lead structure for hit generation.
The B1molecule was divided into fragments, and a pharmaco-
phore approach was applied. The design of new inhibitors started
from the definition of the central (scaffold) structure of the com-
pound that has two fixed planar angles (Fig. 1). The first of them is
determined by either cis- or trans-substitution at the cyclopropane
ring group, whereas the second rigid angle is fixed by the cis- or
trans-substitution at the CHAN double bond. The phenyl group
bound to the cyclopropane ring was also included into the central
structure, as it can be responsible for potential hydrophobic inter-
actions with the enzyme. The heteroatoms (O and N) that are
located in the main structure of B1 are potential hydrogen bond
acceptors. TheOCHANO link is attached to comparatively hy-
Das et al.
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drophobic 3,4-diethoxyphenyl group that also contains oxygen
atoms as potential hydrogen bond acceptors. In construction of
the new compounds, different hydrophobic groups and hydrogen
bond acceptors were used as pharmacophore replacements near
the cyclopropane ring and OCHANO link. A modification of
the central structure, where the cyclopropane ring was replaced
by theOCACO double bond linker was also examined.
By displacing substituents with different pharmacophoric an-
alogues, a set of 60 new potential inhibitor structures was gener-
ated. The fragments having the biggest effect on the binding en-
ergy were selected for further virtual screening of theMolPort and
ZINC (29) databases. Using the substructure search, 70 com-
pounds with suitable pharmacophoric groups were found from
these databases. Their affinity was again estimated by docking to
theCHIKVnsP2 active site. The used docking sitewas surrounded
with amino acid residues Tyr1079, Asn1082, Ser1048, Cys1013,
Ala1046, Tyr1047, Trp1084, Leu1205, and Asp1246; among these,
Cys1013 (from the catalytic dyad) was the most important resi-
due. This docking site is similar to that used in several previous
studies. Thus, in modeling the thiazolidone derivates as CHIKV
nsP2 protease inhibitors, the most important binding amino acid
residue was found to be Tyr1047 (30), while in another study by
the same group, residues Tyr1047, Trp1084, and Asp1246 were
determined as the most important ones (38). Similarly, Bassetto
and coworkers (32) described the docking pose of inhibitors with
the enzyme residues His1083, Cys1013, Asn1082, and Trp1084.
Next the affinities of the generated compounds to the CHIKV
nsP2 protease active site were calculated. The molecular docking
data revealed that the largest effect on the binding free energy
(G) and ligand efficiency (LE) was caused by the variation of
hydrophobic groups. The generated compounds also possess the
cis-, trans-isomerism at the cyclopropane ring or at the double
bond and possible chirality at the terminal acetamidophenyl
groups. For final calculations, isomers and conformations with
the highest binding energy were used. In total 25 compounds were
obtained; of these, 13 compounds were excluded from inhibition
assays due to poor solubility and/or cytotoxicity. Thus, the final
list of analyzed inhibitors consisted of 12 compounds, designated
1 to 12 (Fig. 2); their docking free energies and LE values are
summarized in Table 1.
Determination of inhibitory activities using cell-free pro-
tease assays. In contrast to previous studies of potential inhibitors
of CHIKV nsP2, we first systematically analyzed the ability of the
selected compounds to inhibit the protease activity of the purified
enzyme in cell-free assays. For the assay, based on the use of re-
combinant protein substrate, we first determined the maximally
allowed concentration of DMSO (used as a solvent). It was found
that CHIKV nsP2 protease was fully active in the presence of 10%
DMSO (Fig. 3A). Thus, as all stock solutions of compounds were
10 mM, they could be applied at concentrations up to 1 mM. At
this concentration all compounds, except compound 2, showed at
least some inhibitory activity; the most prominent inhibition was
observed for compounds 1, 3, 4, and 7 to 12 (Fig. 3B). It should be,
however, noted that under these reaction conditions, compounds
7, 8, and 9 formed a visible precipitate in the reaction mixture;
thus, the results with these three compounds in this assaymay not
be reliable. Furthermore, attempts to use this type of assay to re-
veal concentration dependence of inhibition failed to produce
consistent results (data not shown). As a result, we were unable to
make direct comparison of their inhibitory activities, though they
clearly affected the cleavage of recombinant protein substrate to
different extents (Fig. 3B). We also assayed compound B1 along
with compounds B2, B8, B10, and B11 (32). Interestingly, B1 and
B11 failed to show notable inhibition (Fig. 3C). Compounds B2,
B8, and B10 inhibited the cleavage (Fig. 3C), but they also caused
precipitation of components of the reaction mixture. Thus, the
experimentally revealed properties of B1 did not corroborate our
initial hypothesis. Nevertheless, if somewhat surprisingly, wewere
able to select 11 new CHIKV nsP2 protease inhibitors, including
several rather potent ones.
To compare the efficiencies of different inhibitors, a fluores-
cence resonance energy transfer (FRET)-based assay, originally
described for HIV protease (39), was developed and used. This
continuous assay allows gathering of valuable information con-
cerning the initial period of the reaction and can be easily used in
a high-throughput format. The FRET-based assay can also use
recombinant protein based substrates, such as a pair of fluorescent
protein joined by a cleavable linker (40). However, as CHIKV
nsP2 cleaves recombinant protein and properly designed peptide
substrates with similar efficiencies (K. Rausalu, A. Utt, T. Quirin,
F. S. Varghese, E. Žusinaite, P. K. Das, T. Ahola, and A. Merits,
submitted for publication), in this study, the simpler synthetic
peptide substrate was used.
Continuousmonitoring of the reaction progress can be used to
identify different modes of inhibition. For this type of assay, it is
recommended that the substrate be used at a concentration simi-
lar to the Km (41). The Km of CHIKV nsP2 for our peptide sub-
strate is approximately 3M(Rausalu et al., submitted); however,
3 M substrate was found to be insufficient for measuring confi-
dent FRET signal intensity (data not shown). Therefore, the pep-
tide substrate was used at 15 M, which allowed us to balance
between a confident signal window and substrate binding modal-
ity (41). Initially, this assay was carried out in the presence of a 200
M concentration of each inhibitor. The obtained results were
highly similar to those obtained using recombinant protein sub-
strates. Again, compound 2 failed to inhibit CHIKV nsP2 pro-
tease; the same was the case for compounds 5 and 6 (Fig. 4A),
which were also the least potent inhibitors in the previous assay
(Fig. 3B). All the remaining compounds acted as inhibitors; espe-
cially prominent inhibition of the protease activity was observed
FIG 1 Pharmacophoric characterization of the starting compound, B1. The
compound has two terminal aromatic/hydrophobic groups and hydrogen
bonding donor and acceptor centers in the bridge structure.
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with the lower-molecular-mass compounds (Table 1) 10 to 12
(Fig. 4A and B). Although we did not specifically intend to test the
mode of inhibition (in part because not all of the analyzed com-
pounds were promising inhibitors in virus-based assays; see sub-
sequent sections), it was still evident that compounds 1, 7, 8, and 9
appear to be slowly binding inhibitors (Fig. 4A), while com-
pounds 10 to 12 (and possibly compounds 3 and 4 as well) seem to
act as tight binding inhibitors (Fig. 4B) (42).
Finally, compounds 1, 3, 8, and 11, which have EC50s between
1.5 to 34 M in virus inhibition assays (Table 1; see subsequent
sections for details), were also shown to inhibit the cleavage of
peptide substrate in a concentration-dependent manner (Fig. 4C
to F). In this cell-free assay, compound 1 was the least efficient,
with an estimated 50% inhibitory concentration (IC50) of 200
M(Fig. 4C); in contrast, compounds 3 and 11 have IC50s of50
M (Fig. 4D and F). Compound 8, when used at 20 to 100 M,
inhibited the protease activity of CHIKV nsP2 to a roughly similar
extent (Fig. 4E), indicating that its IC50 was also about 50 M.
Synthesis of isomers of compound 1 and analysis of their
inhibitory properties.Analysis of the inhibitory properties of dif-
ferent isomers of the same compound can provide valuable infor-
mation regarding the binding mechanism of the inhibitor to its
target (43). Therefore, this aspect was analyzed with compound 1,
which was shown to be active in both types of cell-free assays (Fig.
3B and 4A and C). Compound 1 (2-{[2-(3,4-dimethylphepyl)cy-
clopropyl]formamido}-2-phenylacetamide) has three asymmet-
ric atoms; hence, the material used in previous assays represents a
mixture of 8 different isomers (Fig. 5). In order to examine which
of these isomers are capable of inhibiting the protease activity of
CHIKVnsP2, all of them (designated 1a to 1d and 1aL to 1dL [Fig.
5]) were synthesized (Fig. 6), purified, and analyzed using the
above-described assays.
It was found that trans-isomers of compound 1 (1c, 1d, 1cL,
and 1dL) acted as potent inhibitors of protease activity (Fig. 7A
andB). In contrast, at 200M cis-isomers 1a, 1b, 1aL, and 1bLhad
nodetectable inhibitory activity in theFRET-basedassay (Fig. 7B).At
FIG 2 Structures of compounds 1 to 12.
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1 mM, 1a, 1aL, and 1bL were able to cause moderate inhibition of
cleavage of the recombinant protein substrate, while compound
1b displayed no inhibitory activity. Thus, the inhibitory activity of
compound 1 clearly depends on cis- or trans-isomerism at the
cyclopropane ring (Fig. 5). The fact that compounds 1aL to 1dL
had properties very similar to those of their counterparts (1a to
1d) indicates that the orientation of the phenyl group (Fig. 5) has
little or no effect on the inhibitory properties of the compound 1
isomers (Fig. 7A and B); based on these data, the isomers 1aL to
1dL were excluded from further analysis.
The concentration dependence of inhibition by compound 1c
(the most active isomer in the recombinant-protein-based assay
[Fig. 7A]) was analyzed using the FRET-based assay. As expected,
clear concentration-dependent inhibition was observed, allowing
rough estimation of the IC50 of compound 1c, which was 100
M (Fig. 7C).
Anti-CHIKV effects of nsP2 inhibitors in infected cells.Rep-
lication of alphaviruses tolerates considerable variation in P1234
processing efficiencies. Thus, viruses lacking processing at 1/2
and/or 2/3 cleavage sites are viable and can replicate to high titers
(44–46). The cleavage of 3/4 sites is absolutely required for infec-
tivity, but even in this case a huge reduction of processing effi-
ciency had little to no effect on virus infection (47). Thus, an
efficient inhibitor of nsP2 protease activity does not necessarily
cause significant reduction of virus replication. Therefore, the ef-
fects of selected compounds on CHIKV multiplication were ana-
lyzed next.
In order to minimize the impact of indirect effects of reduced
protease activity on virus propagation, the assay was carried out in
interferon-negative BHK-21 cells (48). Dose-response curves for
EC50 determination (provided in the supplementalmaterial) were
generated for all 12 compounds that were tested in the cell-free
protease assay. Cytotoxicity assays with these compounds were
also performed in the same cells in parallel. None of the com-
pounds caused any cytotoxicity up to 200 M, the highest con-
centration that was tested. It was observed that compound 1 and
its trans-isomers (1c and 1d) clearly inhibited CHIKV replication,
though the EC50s (27 to 58M)were rathermodest. Consistent
with data from cell-free assays (Fig. 7A and B), cis-isomers of
compound 1 showed little (1a) to no (1b) activity in the antiviral
assay (Table 1). Compounds 2, 5, and 6, none of which inhibited
cleavage of peptide substrate in the cell-free assay (Fig. 4A), also
inhibited CHIKV replicationwith low efficiency (EC50,
70M).
Compounds 3, 11, and 12, which prominently inhibited the pro-
tease activity in the previous assays, also had lower EC50s, between
25 and 47 M. In contrast, compounds 4 and 10, which in the
protease assay behaved similarly to compounds 3 and 11, respec-
tively (Fig. 4B), did not show corresponding antiviral activity (Ta-
ble 1). Perhaps most surprisingly, compounds 7, 8, and 9, which
were slow-binding inhibitors and showed only moderate effi-
ciency in the cell-free assay (Fig. 4A), were themost effective, with
EC50s of 11, 1.5, and 22 M, respectively (Table 1). This suggests
that at least in part their antiviral activity may be due to effects
other than inhibition of protease activity of nsP2.
Compounds 1c, 3, 8, and 11 suppress CHIKVRNA synthesis
and infectious virus release. Next, the effects of selected inhibi-
tors on the synthesis of viral positive-strand RNAs were analyzed.
For this assay, compounds 1c, 3, 8, and 11, all capable of inhibiting
protease activity in a concentration-dependent manner (Fig. 4D
to F and 7C) and having EC50s between 1.5 and 50 M in a virus
inhibition assay (Table 1), were selected. Again, the experiment
was carried out in BHK-21 cells, but in order to synchronize the
infection, a high MOI, 10, was used. The compounds in concen-
trations up to 100 M were added to the cells together with the
virus and were present in growth media for the entire duration of
the assay.
Northern blot analysis revealed that compound 1c had only a
modest effect on the synthesis of CHIKV positive-strand RNAs
(Fig. 8A). Compound 3 displayed classical concentration-depen-
dent inhibition that was detectable already at 50 M and became
more prominent at 100M(Fig. 8A). Compound 8 was unable to
suppress RNA replication at concentrations around its EC50 and
showed relatively weak inhibition only at the two highest concen-
trations (
34-fold above its EC50 for virus propagation). Com-
pound 11 had a moderate effect on RNA synthesis at concentra-
tions of 50 M but caused almost a complete block of RNA
TABLE 1 Docking free energies and ligand efficiencies of analyzed inhibitors
Compound no. Molecular mass (Da) G (kcal/mol) Ligand efficiencya EC50 (M) CC50 (M) SI
b
1 322.4 NAc NA 27 
200 
7.4
1a 322.4 8.02 0.334 82 
200 
2.4
1b 322.4 6.65 0.277 
100 
200 NA
1c 322.4 7.34 0.306 50 
200 
4
1d 322.4 6.97 0.290 57 
200 
3.5
2 320.43 7.49 0.300 73 
200 
2.7
3 382.764 6.53 0.312 33 
200 
6
4 349.358 7.3 0.292 92 
200 
2.1
5 328.793 7.04 0.320 73 
200 
2.7
6 373.244 7.5 0.341 71 
200 
2.8
7 387.4311 8.16 0.291 11 
200 
18.1
8 437.942 8.61 0.297 1.5 
200 
133.3
9 361.437 8.03 0.297 22 
200 
9
10 235.32 6.8 0.453 69 
200 
2.8
11 246.3 6.3 0.394 25 
200 
8
12 271.35 6.77 0.376 47 
200 
4.2
a G/number of heavy atoms.
b SI, selectivity index (CC50/EC50).
c NA, not applicable.
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synthesis at 100 M (4-fold above its EC50). Thus, it was con-
firmed that compounds used in this assay reduced the accumula-
tion of CHIKV positive-strand RNAs.
To obtain more information about the effects of the com-
pounds onCHIKVRNA synthesis, a time-of-addition experiment
was carried out (Fig. 8B). In this assay, all compounds were pres-
ent at higher (100 M) concentrations. Only compound 8 re-
duced virus RNA synthesis in pretreated cells (Fig. 8B). Consistent
with the results of the previous experiment (Fig. 8A), all four com-
pounds were active when added together with the virus, the effect
caused by compound 11 being the most prominent (Fig. 8B).
When compounds were added at 2 h postinfection, their effect on
CHIKV RNA synthesis was, with the exception of compound 11,
minimal (Fig. 8B).
We also analyzed the effects of the compounds on the release of
infectious virus progeny. The experiment was performed as de-
scribed above, except that virus-containing media were harvested
2 h later (at 8 h postinfection) to account for the time needed for
infectious virion formation and release (Fig. 8C). The results were
consistentwith those of theRNA synthesis assay. Again, only com-
pound 8 caused clear reduction of infectious virus production in
pretreated cells (Fig. 8B). In contrast, when present throughout
the assay, all compounds caused clear reduction of virus yield.
Compound 11 was the most efficient inhibitor, resulting in nearly
a 1,000-fold reduction of infectious virus release, followed by
compounds 8 and 1c (Fig. 8C); exactly the same order of relative
potencies was observed in the previous assay (compare Fig. 8B and
C). Finally, with the possible exception of compound 1c, the effi-
ciencies of all the inhibitors were reduced when they were added 4
h postinfection; again, compound 11 stood out as the most effi-
cient inhibitor (Fig. 8C). The striking similarity of the results from
Northern blot and titration experiments clearly indicates that the
FIG 3 Rationally selected compounds inhibit the ability of CHIKVnsP2 to process a recombinant protein substrate. The ratio of enzyme to substrate was1:17.
Reactions were carried out at 30°C for 60 min; products were separated by SDS-PAGE and visualized using Coomassie blue staining. (A) Determination of
maximally tolerated solvent (DMSO) concentration. (B) Effects of 1 mM compounds 1 to 12 (indicated at the top) on the protease activity of CHIKV nsP2. The
image combines three gels that have been rearranged to support the final numbering of compounds; the dotted lines show where different lanes have been
merged. (C) Effects of 1 mM compounds B1, B2, B8, B10, and B11 (indicated at the top) on the protease activity of CHIKV nsP2. The dotted lines show where
different lanes have been merged. The experiments for each panel were repeated at least three times, with highly similar results.
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reduction of RNA synthesis, caused by the presence of the inhib-
itors, is the main contributor to the reduced release of infectious
virions.
DISCUSSION
CHIKV outbreaks in the IndianOcean region and currently in the
Caribbean/Americas have affected the lives of millions of people.
Therefore, the WHO recognizes CHIKV as one of three viral
agents causing neglected tropical diseases (http://www.who.int).
Continued spread of Aedes mosquitoes, capable of transmitting
CHIKV, creates possibilities of new outbreaks in territories with
immunologically naive populations. Thus, development of effi-
cient compounds, capable of inhibiting CHIKV infection, is es-
sential. Furthermore, chemical inhibitors also serve as important
tools for studies of the molecular biology of a virus and its inter-
actions with the host.
The application of target-based modeling resulted in selection
of 12 compounds that were predicted to interact with the active
site of CHIKV nsP2 protease. This represents the first set of
CHIKV nsP2 protease inhibitors for which, in addition to the in
silico predictions, the abilities to inhibit the enzymatic activity of
nsP2 protease and virus replication in cell culture have been ana-
lyzed. At 200M, 75%of these compounds inhibited the protease
activity of nsP2 (Fig. 4A andB); the exceptionswere compounds 2,
5, and 6. Importantly, with the exception of compounds 4 and 10,
all compounds that inhibited the protease activity of nsP2 were
FIG 4 Compounds 1 to 12 inhibit the ability of CHIKV nsP2 to process a peptide substrate. In all assays the enzyme concentration was 78 nM, while the
concentration of the substrate was 15 M. Reactions were carried out at 30°C for 60 min. Vertical axes show EDANS fluorescence in relative fluorescence units
(RFU). Horizontal axes show reaction time. (A) Effects of compounds 1, 2, 5, 6, 7, 8, and 9 at 200 M. (B) Effects of compounds 3, 4, 10, 11, and 12 at 200 M.
(C to F) Concentration-dependent inhibition of protease activity by compounds 1 (C), 3 (D), 8 (E), and 11 (F) is shown. Each graph represents averages from at
least two independent experiments.
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also capable of inhibiting CHIKV replication with EC50s of 50
M. Thus, the efficiency of the applied in silico approaches was
appreciably high, even taking into account that 13 predicted po-
tential inhibitors were excluded fromdetailed analysis due to their
toxicity and/or poor solubility. At a glance, this outcome is some-
what unexpected, as our predictions were based on the structure
of compound B1 (32), which was subsequently demonstrated to
be a very inefficient inhibitor of nsP2 protease activity (Fig. 3C). It
should be mentioned, however, that in their study, Bassetto and
colleagues did not demonstrate that compound B1 inhibits the
enzymatic activity of nsP2 protease; instead, it was shown that it
inhibits virus replication with an EC50 of 5 M (32). The fact
that in this study the majority of compounds, designed based on
B1, were inhibitors of nsP2 (Fig. 3 and 4) is consistent with the
possibility that compound B1 binds, as predicted by Bassetto and
colleagues, to the active-site region of nsP2 but this binding does
not result in the inhibition of protease activity. Thus, the observed
inhibition of CHIKV infection may result from compromising
some other activity of nsP2 instead. This possibility is indirectly
supported by observation that several compounds (most notably
compound 8) analyzed in this study also inhibit CHIKV replica-
tion with much lower EC50s than could be deduced from their
ability to inhibit the protease activity of nsP2 (Fig. 4E andTable 1).
The synthesis and subsequent analysis of stereoisomers of
compound 1 clearly demonstrated that the ability of this com-
pound to inhibit nsP2 protease activity and also its antiviral effi-
ciency depend on the conformation of the inhibitor (Fig. 7 and
Table 1). The cis-trans-isomerism of the cyclopropane ring was
found to be the critical determinant. The docking configuration
for the active isomer 1c in the active site of CHIKV nsP2 protease
reveals that the inhibitor molecule is surrounded by amino acid
residues Ala1010, Asn1011, Ala1046, Tyr1047, Trp1084, Asn1082,
and His1083 (Fig. 7D). The aromatic groups of the inhibitor are
favorably located close to the hydrophobic area surrounded by
Cys1013, Ala1010, Ala1046, and Trp1084. There is also important
hydrogen bonding between either of the amide NOH hydrogens
of the inhibitor molecule and the oxygen atom of the Asn1082
residue (Fig. 7D). At the same time, the phenyl group of com-
pound 1 is turned away from the enzyme binding pocket, and
thus, the relative configuration of it should have little influence on
the compound’s activity, an assumption that was clearly sup-
ported by experimental data (Fig. 7A and B). These findings once
again highlight excellent correlation betweenpredicted and exper-
imentally revealed properties of the compounds used in this study.
Furthermore, conformation-specific inhibition of protease activ-
ity demonstrates the high specificity of the inhibitor and also the
high quality of the recombinant protein, opening the possibility to
cocrystallize the enzyme with its inhibitor, as was recently done
using a peptidomimetic inhibitor of VEEV protease (34). Such
structures may further facilitate development of CHIKV nsP2
protease inhibitors as well as provide valuable information about
the properties and functions of nsP2.
In this study, the activities of the compounds were not only
predicted in silico but also experimentally measured using two
different cell-free protease assays (a recombinant protein and a
FIG 5 Structures of isomers of compound 1.
FIG 6 Schema for the synthesis of isomers 1a to 1d of compound 1. Reagents and conditions: (a) Ph3PMe
Br, t-BuOK, tetrahydrofuran (THF); (b)
N2CHCO2Et, Rh2(OAc)4 (0.5 mol%), dichloromethane (DCM); (c) 2 M aqueous NaOH (0.65 eq), THF-EtOH, room temperature, and then extraction and
chromatography; (d) 2M aqueous NaOH (5 eq), THF-EtOH, 65°C; (e) (COCl)2, THF; (f) D-()-phenylglycinamide,N-ethylmorpholine, 4-(dimethylamino)-
pyridine (DMAP), THF.
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FRET-based peptide cleavage assay) and cell-culture virus inhibi-
tion assay; in addition, the effects of four compounds on the syn-
thesis of positive-stand RNAs and on the release of progeny viri-
ons were revealed. It was anticipated that the use of different
approaches allows confirmation of the findings and, in some
cases, reveals additional important properties of the compounds.
Indeed, it was observed that compounds that affect the cleavage of
recombinant proteins in a similar manner may have different ef-
fects on the cleavage of a peptide substrate. Our data suggest that
there are at least two different types of inhibitors among the ana-
lyzed compounds. Compound 3 displayed a clear concentration-
dependentmode of inhibition (Fig. 4D). In contrast, several com-
pounds, including compound 1 (Fig. 4C) and its active isomers
(Fig. 7B and C), had little to no effect on the initial speed of cleav-
age of peptide substrate, and the inhibition became apparent only
at later time points; this behavior is consistent with properties of
slow-binding inhibitors (49). The existence of different mecha-
nisms of inhibition should be taken into account for analysis of
structure-function relationships, as it may have significant impact
for additional in silico searches for more active compounds.
In most cases the different assays, from in silico predictions to
the analysis of inhibition of virus replication and viral positive-
FIG 7 Inhibitory properties of different stereoisomers of compound 1. (A) Effects of compounds 1a to 1d and 1aL to 1dL on the ability of CHIKV nsP2 to cleave
a recombinant protein substrate. The assay was performed and data are presented as described for Fig. 3. (B) Effects of compounds 1a to 1d and 1aL to 1dL on
the ability of CHIKV nsP2 to cleave a peptide substrate. The assay was performed and data are presented as described for Fig. 4A. (C) Concentration-dependent
inhibition of protease activity by compound 1c. (D)Molecular docking of compound 1c to the active site of CHIKV nsP2 protease. Hydrogen bonding between
either of the amide N-H hydrogens of the inhibitor molecule and the oxygen atom of Asn1082 is shown with a dotted line.
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strand RNA synthesis, produced remarkably consistent results.
Thus, compounds inactive in protease assays were always poor
inhibitors of virus replication; from isomers of compound 1, com-
pound 1b, which had the smallest absolute LE value (Table 1), was
also the only one that also lacked any inhibitory properties (Fig.
7A and B). The existence of such correlations serves as an impor-
tant parameter for the reliability of the results. On this back-
ground, however, compounds that produced seemingly conflict-
ing results deserve specific attention. Compounds 4, 10, and, to a
lesser extent, 12 were all among themost effective inhibitors of the
protease activity of nsP2 (Fig. 3 and 4) but had a low capacity to
inhibit CHIKV replication in cell culture. Likely reasons for this
include poor ability of these compounds to enter cells and/or their
low stability in cell culture assay. It is, however, also possible that
these compounds could only bind to and inactivate free nsP2 but
were unable to do the same in infected cells, where nsP2 exists as
FIG 8 Compounds 3, 8, and 11 inhibit CHIKV positive-strand RNA synthesis and release of infectious virions. (A) Demonstration of concentration-dependent
inhibition. Compounds (names and concentrations are shown above the panels) were added to the cells together with virus and present throughout experiment.
Control cells were treatedwith an appropriate amount of a solvent control (DMSO). Total RNAswere extracted and separated; CHIKVpositive-standRNAswere
detected using a probe complementary to the 3= untranslated region of the virus genome. Arrows point out the positions of CHIKV genomic and subgenomic
RNAs. (B) Time-of-addition assay (inhibition of positive-strand RNA synthesis). The illustration at the top represents the schema of the experiment. All
compounds were used at 100M; samples were analyzed and results are presented as described for panel A. (C) Time-of-addition assay (inhibition of infectious
virus release). The illustration at the top represents the schema of the experiment. All compounds were used at 100 M; amounts of released virions were
determined using plaque titration. Results were normalized to those from DMSO-treated control cells and expressed as log10 fold reduction of infectious virus
titers. Each column represents an average from two experiments performed in triplicate; error bars represent standard deviations.
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part of a multienzyme complex and its ability to process its cleav-
age sites is altered by presentation of these sequences to the en-
zyme (45).
The ability of compounds 1c, 3, 8, and 11 to inhibit the pro-
duction of progeny virions clearly correlates with their ability to
suppress viral positive-strand RNA synthesis (Fig. 8B and C). The
inhibitory effects were always more prominent when compounds
were present throughout the infection. However, remarkably,
when added as late as 4 h postinfection, all these compounds were
still able to suppress infectious virus production. Thus, these com-
pounds inhibit someprocess still ongoing at this stage of infection,
nsP2-mediated cleavage of CHIKV P1234 polyprotein being an
obvious candidate for this role. This does not, however, exclude
the possibility of other targets for these inhibitors. As discussed
below, compound 8 almost certainly has another mode(s) of ac-
tion. Interestingly also, at 100Mcompound 11 is a very efficient
inhibitor of viral RNA synthesis, and this inhibition is clearly
translated into prominent suppression of progeny virus release;
below 100 M, however, this compound sharply loses its activity
(Fig. 8A). As the inhibition profile of virus positive-strand RNA
synthesis (Fig. 8A) is clearly different from that of peptide sub-
strate cleavage (Fig. 4F), compound 11may also have other targets
in the virus-infected cells. Additional experiments (such as isola-
tion and characterization of drug-resistant CHIKV mutants) are
needed to characterize the true modes of actions of the different
inhibitors.
The most interesting behavior was observed for compound 8
and, to a lesser extent, for compound 7. Both of these compounds
were clearlymore potent inhibitors of virus replication (EC50s, 1.5
M and 11 M, respectively) than could be expected based on
their potency to inhibit the protease activity of nsP2. Thus, the
IC50 of compound 8 in the FRET assay was 50 M, 
25-fold
higher than its EC50 in the virus inhibition assay (Table 1). This
resembles the properties of compound B1, which was reported to
have an EC50 of5 M (32), yet it was virtually unable to inhibit
the protease activity of CHIKV nsP2 (Fig. 3C), suggesting the ex-
istence of an additional mechanism(s) of action. This possibility
was further emphasized by the finding that at concentrations of
50 M, compound 8 is a rather inefficient inhibitor of CHIKV
positive-strand RNA synthesis (Fig. 8A). Among compounds an-
alyzed in this study, compound 8 has the biggest calculated abso-
lute G value (8.61 kcal/mol [Table 1]), indicating efficient
binding to nsP2. It should also be noted that compound 8 has also
the highest molecular mass among the analyzed compounds (Ta-
ble 1). It is possible that binding of compound 8 has only a mod-
erate effect on the protease activity of nsP2 and, consequently, also
on the synthesis of viral RNAs. Instead, it could be speculated that
binding of compound 8 to its target affects more prominently
some other function(s) of nsP2; the same may be true for other
compounds, such as 7 andB1. As the pronounced inhibitory effect
of compound 8 was detected in experiments carried out using low
MOI (virus inhibition) but not using a highMOI (positive-strand
RNA synthesis), it can be speculated that compound 8 may also
inhibit virus spread in cell culture; this property is crucial under
low-MOI, but not under high-MOI, conditions. Previous studies
carried out usingVEEVhave established a functional link between
nsP2 and alphavirus particle formation. Thus, it has been ob-
served that replication of a VEEV mutant in which the viral sub-
genomic promoter was replaced by an encephalomyocarditis vi-
rus internal ribosomal entry site was strongly enhanced by
adaptive mutations located in the helicase region nsP2 (50). Re-
cently, it was also shown that both titers and cytotoxic effects of a
VEEVmutant harboringmultiplemutations in the capsid protein
were increased by adaptive mutations mapped to the protease
domain of nsP2 or to the N-terminal part of nsP2 (51), which is
known to act as a cofactor of alphavirus nsP2 protease (52). There-
fore, it could be put forth that indirect inhibition efficiencies of
some compounds may originate from effects of these compounds
on the formation and release of virus particles; this topic is under
investigation in our laboratories. In addition, pretreatment of cells
with compound 8 inhibits both viral positive-strand RNA synthe-
sis and infectious virus production (Fig. 8B and C). This also in-
dicates an existence of yet another mechanism of action which is
unlikely to be mediated by the suppression of nsP2’s activities.
Therefore, themechanismmay be cell mediated rather than based
on the direct inhibition of CHIKV replication; its analysis also
represents a topic for further studies.
To our knowledge, this study represents the first example of a
rational search for inhibitors against CHIKV nsP2 protease in
which in silico predictions were combined with the use of cell-free
protease assays and cell-based virus inhibition assays. Several
novel inhibitors were identified, providing new information for
development of further antiviral compounds as well as tools to
studyCHIKV infection. Furthermore, taking into account that the
known 3D structures of alphaviral nsP2 proteases are similar to
each other, it is also reasonable to expect that at least some of the
inhibitors analyzed in this study are also active against other al-
phaviruseswhich, similar toCHIKV, have the potential to become
serious human pathogens.
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